[
  {
    "date": "2023-12-30",
    "symbol": "CMMB",
    "period": "FY",
    "entitycentralindexkey": 1534248,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "documenttype": "20-F",
    "documentregistrationstatement": "false",
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalyearfocus": 2023,
    "documentperiodenddate": "2023-12-31",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "documentshellcompanyreport": "false",
    "entityfilenumber": "001-40490",
    "entityregistrantname": "Chemomab Therapeutics Ltd.",
    "entityincorporationstatecountrycode": "L3",
    "entityaddressaddressline1": "Kiryat               Atidim, Building 7",
    "entityaddresscityortown": ",               Tel Aviv",
    "entityaddresscountry": "IL",
    "entityaddresspostalzipcode": 6158002,
    "cityareacode": 855,
    "contactpersonnelname": "Sigal Fattal",
    "localphonenumber": "492-5563",
    "security12btitle": "American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share",
    "tradingsymbol": "CMMB",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entityemerginggrowthcompany": "true",
    "documentaccountingstandard": "U.S. GAAP",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "entityshellcompany": "false",
    "entitycommonstocksharesoutstanding": 284094700,
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel",
    "auditorfirmid": 1057,
    "documentfinstmterrorcorrectionflag": "false",
    "cashandcashequivalentsatcarryingvalue": 9292000,
    "depositsassetscurrent": 10492000,
    "restrictedcashcurrent": 76000,
    "prepaidexpenseandotherassetscurrent": 1037000,
    "assetscurrent": 20897000,
    "prepaidexpensenoncurrent": 559000,
    "propertyplantandequipmentnet": 303000,
    "operatingleaserightofuseasset": 392000,
    "assetsnoncurrent": 1254000,
    "assets": 22151000,
    "accountspayabletradecurrent": 516000,
    "accruedliabilitiescurrent": 3423000,
    "employeerelatedliabilitiescurrent": 823000,
    "operatingleaseliabilitycurrent": 76000,
    "liabilitiescurrent": 4838000,
    "operatingleaseliabilitynoncurrent": 316000,
    "liabilitiesnoncurrent": 316000,
    "liabilities": 5154000,
    "additionalpaidincapital": 105675000,
    "retainedearningsaccumulateddeficit": -88678000,
    "stockholdersequity": 16997000,
    "liabilitiesandstockholdersequity": 22151000,
    "commonstocksharesauthorized": 650000000,
    "commonstocksharesissued": 284094700,
    "sharesoutstanding": 284094700,
    "researchanddevelopmentexpense": 18381000,
    "generalandadministrativeexpense": 7078000,
    "operatingexpenses": 25459000,
    "nonoperatingincomeexpense": 1238000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -24221000,
    "netincomeloss": -24221000,
    "earningspersharebasic": 0.103,
    "earningspersharediluted": 0.103,
    "weightedaveragenumberofsharesoutstandingbasic": 234998859,
    "weightedaveragenumberofdilutedsharesoutstanding": 234998859,
    "stockissuedduringperiodvaluesharebasedcompensation": 1491000,
    "stockissuedduringperiodsharesnewissues": 3445520,
    "stockandwarrantsissuedduringperiodvaluenewissues": 2924000,
    "stockandwarrantsissuedduringperiodnewissues": 51458000,
    "stockissuedduringperiodvaluetreasurystockreissued": 1218000,
    "stockissuedduringperiodsharestreasurystockreissued": 11640460,
    "profitloss": -24221000,
    "depreciation": 67000,
    "sharebasedcompensation": 1491000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": -903000,
    "increasedecreaseinaccountspayabletrade": -1172000,
    "increasedecreaseinaccruedliabilities": 45000,
    "increasedecreaseinemployeerelatedliabilities": -737000,
    "increasedecreaseinoperatingleaseliability": 13000,
    "netcashprovidedbyusedinoperatingactivities": -23611000,
    "paymentsforinvestmentindeposits": -15882000,
    "paymentstoacquirepropertyplantandequipment": 3000,
    "netcashprovidedbyusedininvestingactivities": 15879000,
    "proceedsfromsaleoftreasurystock": 580000,
    "proceedsfromotherequity": 2924000,
    "netcashprovidedbyusedinfinancingactivities": 3504000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -4228000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 9368000,
    "incometaxesreceived": 187000,
    "interestreceived": 1463000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 392000,
    "percentageofmonthlydepositsrate": 0.0833,
    "severancecosts1": 86000,
    "propertyplantandequipmentsalvagevaluepercentage": 0.33,
    "annualratesofdepreciation": "over the shorter of the lease term or the estimated useful life of the improvement",
    "receivablesfromgovernmentinstitutions": 289000,
    "prepaidexpensecurrent": 748000,
    "propertyplantandequipmentgross": 68000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 226000,
    "lesseeoperatingleaseoptiontoextend": "three years",
    "bankguaranteestopropertyowner": 77000,
    "reassessmentofrightofuseasset": 392000,
    "operatingleaseliability": 392000,
    "operatingleaseimpairmentloss": 392000,
    "debtinstrumentinterestrateincreasedecrease": 0.09,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 115000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 121000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 121000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfive": 107000,
    "lesseeoperatingleaseliabilitypaymentsdue": 464000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 72000,
    "longtermpurchasecommitmentdescription": "$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.",
    "percentageofroyaltypaymentsonsaleofproduct": 0.03,
    "maximumpercentageofpaymentsofroyalties": 1,
    "cumulativeamountsofgrantsreceivedandrecognized": 1227000,
    "royaltyexpense": 4832000,
    "restrictedinvestments": 76000,
    "proceedsfromsaleofadss": 1371000,
    "stockissuedduringperiodamericandepositorysharesnewissues": 772900,
    "saleofstockspricepershare": 1.83,
    "numberofstockreservedforissuance": 28443060,
    "numberofstockadssresveredforissuance": 1422153,
    "numberofadssoptionsissuableoutstanding": 341322,
    "numberofoptionsissuableoutstanding": 6826440,
    "numberofadssvestedandexercisable": 319708,
    "numberofoptionsvestedandexercisable": 6394160,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 0.3,
    "sharebasedcompensationarrangementbysharebasedpaymentawardadsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 5.98,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 16634300,
    "sharebasedcompensationarrangementbysharebasedpaymentawardadsforfeituresinperiod": 831715,
    "weightedaveragepriceofrepurchaseofamericandepositaryreceipts": 0.96,
    "totalconsiderationofrepurchaseofamericandepositaryreceipts": 1553000,
    "allocatedsharebasedcompensationexpense": 407000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.16,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 0.39,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.07,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 29873100,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 15055180,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P5Y11M26D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageremainingcontractualterm": "P5Y10M9D",
    "shareprice": 0.07,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 0.06,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P4Y6M10D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.9779,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 1.1294,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0371,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0443,
    "consultantsandsubcontractorsexpense": 14014000,
    "officerscompensation": 3362000,
    "rentandmaintenanceresearchanddevelopmentexpense": 137000,
    "sharebasedcompensationresearchanddevelopmentexpense": 407000,
    "otherresearchanddevelopmentexpense": 461000,
    "salariesandwages": 2545000,
    "professionalfees": 2139000,
    "sharebasedcompensationgeneralandadministrativeexpense": 1084000,
    "noninterestexpensedirectorsfees": 258000,
    "generalinsuranceexpense": 648000,
    "rentandmaintenancegeneralandadministrativeexpense": 81000,
    "othergeneralandadministrativeexpense": 323000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.23,
    "taxcreditcarryforwardamount": 165000000,
    "valuationallowancedeferredtaxassetchangeinamount": 2300000,
    "expectstoreceiveamountofchemomabtherapeuticsinc": 183000,
    "deferredtaxassetsoperatinglosscarryforwards": 38258000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1163000,
    "deferredtaxassetsinprocessresearchanddevelopment": 4041000,
    "deferredtaxassetsother": 9000,
    "deferredtaxassetsgross": 43471000,
    "deferredtaxassetsvaluationallowance": 43471000,
    "currencytransactionlossvaluationallowance": -3295000,
    "incometaxexpensevaluationallowance": 5571000,
    "effectiveincometaxratecontinuingoperations": 0.23,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -5571000,
    "changeintemporarydifferencesfordeferredtaxesnotrecognized": -1177000,
    "incometaxreconciliationforeignincometaxratedifferential": 10000,
    "incometaxreconciliationnondeductibleexpense": 346000,
    "lossesandbenefitsfortaxpurposesforyearforwhichdeferredtaxeswerenotrecorded": 6392000,
    "otherliabilitiescurrent": 564000,
    "relatedpartytransactionsalariesandrelatedexpensesfromtransactionswithrelatedparty": 2795000,
    "relatedpartytransactionsharebasedpaymentsfromtransactionswithrelatedparty": 1304000,
    "relatedpartytransactionprofessionalservicesfromtransactionswithrelatedparty": 258000,
    "relatedpartytransactionresearchanddevelopmentexpensefromtransactionswithrelatedparty": 36000,
    "costofrevenue": 4393000,
    "incomelossfromcontinuingoperationsperbasicshare": 0.103,
    "incomelossfromcontinuingoperationsperdilutedshare": 0.103,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 29873100
  },
  {
    "date": "2022-12-30",
    "symbol": "CMMB",
    "period": "FY",
    "entitycentralindexkey": 1534248,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "December 31",
    "documentfiscalyearfocus": 2022,
    "documentperiodenddate": "December 31, 2022",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-38807",
    "entityregistrantname": "CHEMOMAB THERAPEUTICS LTD.",
    "entityincorporationstatecountrycode": "Israel",
    "entitytaxidentificationnumber": "81-3676773",
    "entityaddressaddressline1": "Kiryat Atidim",
    "entityaddressaddressline2": "Building 7",
    "entityaddresscityortown": "Tel Aviv",
    "entityaddresscountry": "Israel",
    "entityaddresspostalzipcode": 6158002,
    "cityareacode": 972,
    "localphonenumber": "77-331-0156",
    "security12btitle": "Ordinary shares, no par value per share",
    "tradingsymbol": "n/a",
    "securityexchangename": "Nasdaq",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "true",
    "entityshellcompany": "true",
    "entitypublicfloat": 37900000,
    "entitycommonstocksharesoutstanding": 220996240,
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel",
    "auditorfirmid": 1057,
    "cashandcashequivalentsatcarryingvalue": 100000,
    "depositsassetscurrent": 26374000,
    "restrictedcashcurrent": 77000,
    "prepaidexpenseandotherassetscurrent": 1766000,
    "assetscurrent": 41736000,
    "prepaidexpensenoncurrent": 733000,
    "propertyplantandequipmentnet": 367000,
    "operatingleaserightofuseasset": 227000,
    "assetsnoncurrent": 1327000,
    "assets": 43063000,
    "accountspayabletradecurrent": 1688000,
    "accruedliabilitiescurrent": 58000,
    "employeerelatedliabilitiescurrent": 891000,
    "operatingleaseliabilitycurrent": 123000,
    "liabilitiescurrent": 6749000,
    "operatingleaseliabilitynoncurrent": 91000,
    "liabilitiesnoncurrent": 91000,
    "liabilities": 6840000,
    "treasurystockvalue": 1218000,
    "additionalpaidincapital": 101260000,
    "retainedearningsaccumulateddeficit": -63819000,
    "stockholdersequity": -63819000,
    "liabilitiesandstockholdersequity": 43063000,
    "commonstocksharesauthorized": 650000000,
    "commonstocksharesissued": 232636700,
    "sharesoutstanding": -11640460,
    "treasurystockshares": 11640460,
    "researchanddevelopmentexpense": 16977000,
    "generalandadministrativeexpense": 11556000,
    "operatingexpenses": 28533000,
    "nonoperatingincomeexpense": 353000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": -28180000,
    "incometaxexpensebenefit": -534000,
    "netincomeloss": -27646000,
    "earningspersharebasic": 0.121,
    "earningspersharediluted": 0.121,
    "weightedaveragenumberofsharesoutstandingbasic": 227589288,
    "weightedaveragenumberofdilutedsharesoutstanding": 227589288,
    "stockissuedduringperiodvaluesharebasedcompensation": 3211000,
    "stockissuedduringperiodsharesnewissues": 11730800,
    "stockandwarrantsissuedduringperiodvaluenewissues": 267000,
    "stockandwarrantsissuedduringperiodnewissues": 2576400,
    "stockissuedduringperiodvaluestockoptionsexercised": 143000,
    "stockissuedduringperiodsharesstockoptionsexercised": 1970000,
    "stockissuedduringperiodvaluetreasurystockreissued": -1218000,
    "stockissuedduringperiodsharestreasurystockreissued": -11640460,
    "profitloss": -27646000,
    "depreciation": 58000,
    "sharebasedcompensation": 3211000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 64000,
    "increasedecreaseinaccountspayabletrade": 352000,
    "increasedecreaseinaccruedliabilities": 2823000,
    "increasedecreaseinemployeerelatedliabilities": 907000,
    "increasedecreaseinoperatingleaseliability": -11000,
    "netcashprovidedbyusedinoperatingactivities": -20370000,
    "paymentsforinvestmentindeposits": -19601000,
    "paymentstoacquirepropertyplantandequipment": 68000,
    "netcashprovidedbyusedininvestingactivities": 19533000,
    "proceedsfromstockoptionsexercised": 143000,
    "paymentsofstockissuancecosts": 1218000,
    "proceedsfromotherequity": 267000,
    "netcashprovidedbyusedinfinancingactivities": -808000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": -1645000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 13596000,
    "incometaxesreceived": 351000,
    "incometaxespaidnet": 5000,
    "interestreceived": 972000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 17000,
    "percentageofmonthlydepositsrate": 0.0833,
    "severancecosts1": 142000,
    "incrementalborrowingrateofleases": 0.05,
    "propertyplantandequipmentsalvagevaluepercentage": 0.07,
    "annualratesofdepreciation": "over the shorter of the lease term or the estimated useful life of the improvement",
    "receivablesfromgovernmentinstitutions": 459000,
    "prepaidexpensecurrent": 1307000,
    "propertyplantandequipmentgross": 532000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 165000,
    "operatingleaseliability": 214000,
    "operatingleaseimpairmentloss": 17000,
    "debtinstrumentinterestrateincreasedecrease": 0.05,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 126000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 93000,
    "lesseeoperatingleaseliabilitypaymentsdue": 219000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 5000,
    "longtermpurchasecommitmentdescription": "$200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than $600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.",
    "percentageofroyaltypaymentsonsaleofproduct": 0.03,
    "maximumpercentageofpaymentsofroyalties": 1,
    "cumulativeamountsofgrantsreceivedandrecognized": 1227000,
    "royaltyexpense": 5222000,
    "restrictedinvestments": 77000,
    "aggregateofferingpriceofatmarketofferingagreement": 18125000,
    "proceedsfromsaleofadss": 275000,
    "stockissuedduringperiodamericandepositorysharesnewissues": 586540,
    "saleofstockspricepershare": 2.11,
    "numberofstockreservedforissuance": 12511620,
    "numberofstockadssresveredforissuance": 625581,
    "numberofadssoptionsissuableoutstanding": 1173037,
    "numberofoptionsissuableoutstanding": 23460740,
    "numberofadssvestedandexercisable": 21377,
    "numberofoptionsvestedandexercisable": 427540,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 0.35,
    "sharebasedcompensationarrangementbysharebasedpaymentawardadsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 6.98,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 1240120,
    "sharebasedcompensationarrangementbysharebasedpaymentawardadsforfeituresinperiod": 62006,
    "allocatedsharebasedcompensationexpense": 3211000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.33,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 0.07,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 0.32,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.16,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 35191540,
    "stockissuedduringperiodsharesstockoptionsexercised1": 1970000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 11398400,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": 7.42,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageremainingcontractualterm": 7.8,
    "shareprice": 0.16,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 0.257,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": 6.28,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.8369,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 0.8431000000000001,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0175,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0414,
    "consultantsandsubcontractorsexpense": 13052000,
    "officerscompensation": 2867000,
    "rentandmaintenanceresearchanddevelopmentexpense": 245000,
    "sharebasedcompensationresearchanddevelopmentexpense": 448000,
    "otherresearchanddevelopmentexpense": 365000,
    "salariesandwages": 3435000,
    "professionalfees": 2596000,
    "sharebasedcompensationgeneralandadministrativeexpense": 2763000,
    "noninterestexpensedirectorsfees": 231000,
    "generalinsuranceexpense": 1084000,
    "rentandmaintenancegeneralandadministrativeexpense": 24000,
    "othergeneralandadministrativeexpense": 1423000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.21,
    "taxcreditcarryforwardamount": 159000000,
    "valuationallowancedeferredtaxassetchangeinamount": 5200000,
    "receivedamountofchemomabtherapeuticsinc": 351000,
    "deferredtaxassetsoperatinglosscarryforwards": 36550000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1774000,
    "deferredtaxassetsinprocessresearchanddevelopment": 2858000,
    "deferredtaxassetsother": 13000,
    "deferredtaxassetsgross": 41195000,
    "deferredtaxassetsvaluationallowance": 41195000,
    "currencytransactionlossvaluationallowance": -1316000,
    "incometaxexpensevaluationallowance": 6481000,
    "effectiveincometaxratecontinuingoperations": 0.23,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -6481000,
    "changeintemporarydifferencesfordeferredtaxesnotrecognized": -1696000,
    "incometaxreconciliationforeignincometaxratedifferential": 20000,
    "incometaxreconciliationnondeductibleexpense": 744000,
    "lossesandbenefitsfortaxpurposesforyearforwhichdeferredtaxeswerenotrecorded": 6879000,
    "duetorelatedpartiescurrent": 949000,
    "relatedpartytransactionsalariesandrelatedexpensesfromtransactionswithrelatedparty": 2409000,
    "relatedpartytransactionsharebasedpaymentsfromtransactionswithrelatedparty": 2466000,
    "relatedpartytransactionprofessionalservicesfromtransactionswithrelatedparty": 231000,
    "relatedpartytransactionresearchanddevelopmentexpensefromtransactionswithrelatedparty": 36000,
    "relatedpartycosts": 5142000,
    "incomelossfromcontinuingoperationsperbasicshare": 0.121,
    "incomelossfromcontinuingoperationsperdilutedshare": 0.121,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 35191540
  },
  {
    "date": "2021-12-30",
    "symbol": "CMMB",
    "period": "FY",
    "entitycentralindexkey": 1534248,
    "documentfiscalperiodfocus": "FY",
    "amendmentflag": "false",
    "documenttype": "10-K",
    "currentfiscalyearenddate": "--12-31",
    "documentfiscalyearfocus": 2021,
    "documentperiodenddate": "2021-12-31",
    "documentannualreport": "true",
    "documenttransitionreport": "false",
    "entityfilenumber": "001-38807",
    "entityregistrantname": "CHEMOMAB THERAPEUTICS LTD.",
    "entityincorporationstatecountrycode": "L3",
    "entitytaxidentificationnumber": "81-3676773",
    "entityaddressaddressline1": "Kiryat Atidim",
    "entityaddressaddressline2": "Building 7",
    "entityaddresscityortown": "Tel Aviv",
    "entityaddresscountry": "IL",
    "entityaddresspostalzipcode": 6158002,
    "cityareacode": 972,
    "localphonenumber": "77-331-0156",
    "security12btitle": "American Depositary Shares, each representing twenty (20) ordinary shares, no par value per share",
    "tradingsymbol": "CMMB",
    "securityexchangename": "NASDAQ",
    "entitywellknownseasonedissuer": "No",
    "entityvoluntaryfilers": "No",
    "entitycurrentreportingstatus": "Yes",
    "entityinteractivedatacurrent": "Yes",
    "entityfilercategory": "Non-accelerated Filer",
    "entitysmallbusiness": "true",
    "entityemerginggrowthcompany": "true",
    "entityextransitionperiod": "false",
    "icfrauditorattestationflag": "false",
    "entityshellcompany": "false",
    "auditorname": "Somekh Chaikin",
    "auditorlocation": "Tel Aviv, Israel",
    "auditorfirmid": 1057,
    "cashandcashequivalentsatcarryingvalue": 15186000,
    "depositsassetscurrent": 45975000,
    "prepaidexpenseandotherassetscurrent": 1527000,
    "assetscurrent": 62688000,
    "prepaidexpensenoncurrent": 908000,
    "restrictedcashnoncurrent": 55000,
    "propertyplantandequipmentnet": 357000,
    "operatingleaserightofuseasset": 345000,
    "assetsnoncurrent": 1665000,
    "assets": 64353000,
    "accountspayabletradecurrent": 1336000,
    "accruedliabilitiescurrent": 555000,
    "employeerelatedliabilitiescurrent": 653000,
    "operatingleaseliabilitycurrent": 106000,
    "liabilitiescurrent": 2650000,
    "operatingleaseliabilitynoncurrent": 237000,
    "liabilitiesnoncurrent": 237000,
    "liabilities": 2887000,
    "additionalpaidincapital": 97639000,
    "retainedearningsaccumulateddeficit": -36173000,
    "stockholdersequity": 61466000,
    "liabilitiesandstockholdersequity": 64353000,
    "commonstocksharesauthorized": 650000000,
    "commonstocksharesissued": 228090300,
    "sharesoutstanding": 228090300,
    "researchanddevelopmentexpense": 6334000,
    "generalandadministrativeexpense": 6033000,
    "operatingexpenses": 12367000,
    "financeincomeexpensesnet": -111000,
    "netincomeloss": -12478000,
    "earningspersharebasicanddiluted": 0.06,
    "weightedaveragenumberofshareoutstandingbasicanddiluted": 207468650,
    "stockissuedduringperiodvaluesharebasedcompensation": 2019000,
    "effectofreversecapitalizationtransaction": 2476000,
    "effectofreversecapitalizationtransactionshares": 152299702,
    "stockandwarrantsissuedduringperiodvaluenewissues": 58637000,
    "stockandwarrantsissuedduringperiodnewissues": 66381520,
    "stockissuedduringperiodvaluestockoptionsexercised": 10000,
    "stockissuedduringperiodsharesstockoptionsexercised": 134240,
    "profitloss": -12478000,
    "depreciation": 34000,
    "sharebasedcompensation": 2019000,
    "increasedecreaseinprepaiddeferredexpenseandotherassets": 2058000,
    "increasedecreaseinaccountspayabletrade": 1175000,
    "increasedecreaseinaccruedliabilities": -1279000,
    "increasedecreaseinemployeerelatedliabilities": 215000,
    "increasedecreaseinoperatingleaseliability": -2000,
    "netcashprovidedbyusedinoperatingactivities": -12374000,
    "paymentsforinvestmentindeposits": 45951000,
    "longtermleasedeposit": 4000,
    "proceedsfromsaleofotherassetsinvestingactivities": 1000000,
    "paymentstoacquirepropertyplantandequipment": 239000,
    "netcashprovidedbyusedininvestingactivities": -45186000,
    "cashacquiredinmerger": 2427000,
    "proceedsfromstockoptionsexercised": 10000,
    "proceedsfromotherequity": 58637000,
    "netcashprovidedbyusedinfinancingactivities": 61074000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalentsperiodincreasedecreaseincludingexchangerateeffect": 3514000,
    "cashcashequivalentsrestrictedcashandrestrictedcashequivalents": 15241000,
    "rightofuseassetobtainedinexchangeforoperatingleaseliability": 345000,
    "liabilitiesassumed1": 49000,
    "percentageofmonthlydepositsrate": 0.0833,
    "severancecosts1": 116000,
    "propertyplantandequipmentsalvagevaluepercentage": 0.33,
    "annualratesofdepreciation": "over the shorter of the lease term or the estimated useful life of the improvement",
    "receivablesfromgovernmentinstitutions": 179000,
    "prepaidexpensecurrent": 1348000,
    "propertyplantandequipmentgross": 43000,
    "accumulateddepreciationdepletionandamortizationpropertyplantandequipment": 107000,
    "operatingrightofuseassetsandoperatingleaseliabilities": 345000,
    "operatingleaseimpairmentloss": 345000,
    "debtinstrumentinterestrateincreasedecrease": 0.052,
    "lesseeoperatingleaseliabilitypaymentsdueyeartwo": 121000,
    "lesseeoperatingleaseliabilitypaymentsdueyearthree": 133000,
    "lesseeoperatingleaseliabilitypaymentsdueyearfour": 117000,
    "lesseeoperatingleaseliabilitypaymentsdue": 371000,
    "lesseeoperatingleaseliabilityundiscountedexcessamount": 28000,
    "operatingleaseliability": 343000,
    "longtermpurchasecommitmentdescription": "USD 200 thousand upon the grant of FDA or equivalent agency marketing approval in Europe and/or Asia for each Licensed Product. Payment in the aggregate shall not be more than USD 600 thousand per each Licensed Product, provided that for each jurisdiction, payment shall be made only once.",
    "percentageofroyaltypaymentsonsaleofproduct": 0.03,
    "maximumpercentageofpaymentsofroyalties": 1,
    "cumulativeamountsofgrantsreceivedandrecognized": 1227000,
    "royaltyexpense": 2590000,
    "restrictedinvestments": 55000,
    "proceedsfromsaleofadss": 15917000,
    "stockissuedduringperiodamericandepositorysharesnewissues": 699806,
    "saleofstockspricepershare": 22.75,
    "numberofstockadssresveredforissuance": 1422153,
    "numberofadssoptionsissuableoutstanding": 1326723,
    "numberofadssvestedandexercisable": 452230,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingperiodincreasedecreaseweightedaverageexerciseprice": 2.75,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsforfeituresinperiod": 35653,
    "allocatedsharebasedcompensationexpense": 137000,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageexerciseprice": 0.38,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsexercisesinperiodweightedaverageexerciseprice": 0.08,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsforfeituresinperiodweightedaverageexerciseprice": 1.25,
    "sharebasedcompensationarrangementsbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageexerciseprice": 0.62,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingnumber": 27003260,
    "stockissuedduringperiodsharesstockoptionsacquiredinmerger": 609535,
    "stockissuedduringperiodsharesstockoptionsexercised1": 134220,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodgross": 17784640,
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsoutstandingweightedaverageremainingcontractualterm2": "P8Y1M13D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardoptionsgrantsinperiodweightedaverageremainingcontractualterm": "P9Y9M14D",
    "shareprice": 9.44,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexerciseprice": 9.44,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedterm1": "P5Y8M23D",
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityrateminimum": 0.6593,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsexpectedvolatilityratemaximum": 0.7088,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestrateminimum": 0.0136,
    "sharebasedcompensationarrangementbysharebasedpaymentawardfairvalueassumptionsriskfreeinterestratemaximum": 0.0164,
    "consultantsandsubcontractorsexpense": 3894000,
    "officerscompensation": 1789000,
    "rentandmaintenanceresearchanddevelopmentexpense": 114000,
    "sharebasedcompensationresearchanddevelopmentexpense": 137000,
    "otherresearchanddevelopmentexpense": 400000,
    "salariesandwages": 943000,
    "professionalfees": 1695000,
    "sharebasedcompensationgeneralandadministrativeexpense": 1882000,
    "noninterestexpensedirectorsfees": 244000,
    "generalinsuranceexpense": 1024000,
    "rentandmaintenancegeneralandadministrativeexpense": 29000,
    "othergeneralandadministrativeexpense": 216000,
    "effectiveincometaxratereconciliationatfederalstatutoryincometaxrate": 0.23,
    "taxcreditcarryforwardamount": 143000000,
    "deferredtaxassetsoperatinglosscarryforwards": 33396000,
    "deferredtaxassetstaxdeferredexpensecompensationandbenefitssharebasedcompensationcost": 1147000,
    "deferredtaxassetsinprocessresearchanddevelopment": 1449000,
    "deferredtaxassetsother": 38000,
    "deferredtaxassetsgross": 36030000,
    "deferredtaxassetsvaluationallowance": 36030000,
    "valuationallowancedeferredtaxassetchangeinamount": 2600000,
    "currencytransactionlossvaluationallowance": 2425000,
    "taxassetsacquiredthroughmergervaluationallowance": 24535000,
    "incometaxexpensevaluationallowance": 2870000,
    "incomelossfromcontinuingoperationsbeforeincometaxesextraordinaryitemsnoncontrollinginterest": 12478000,
    "effectiveincometaxratecontinuingoperations": 0.23,
    "incometaxreconciliationincometaxexpensebenefitatfederalstatutoryincometaxrate": -2870000,
    "lossesandbenefitsfortaxpurposesforyearforwhichdeferredtaxeswerenotrecorded": -2870000,
    "duetorelatedpartiescurrent": 350000,
    "relatedpartytransactionsalariesandrelatedexpensesfromtransactionswithrelatedparty": 1255000,
    "relatedpartytransactionsharebasedpaymentsfromtransactionswithrelatedparty": 1775000,
    "relatedpartytransactionprofessionalservicesfromtransactionswithrelatedparty": 244000,
    "relatedpartytransactionresearchanddevelopmentexpensefromtransactionswithrelatedparty": 36000,
    "relatedpartycosts": 3310000,
    "incomelossfromcontinuingoperationsperbasicanddilutedshare": 0.06,
    "antidilutivesecuritiesexcludedfromcomputationofearningspershareamount": 27003260
  }
]